Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.


NDAQ:LEXX - Post by User

Bullboard Posts
Comment by voileon Nov 19, 2016 8:53am
86 Views
Post# 25484425

RE:FYI

RE:FYI This was written by Chris Parry, who I used to enjoy reading.  But he now runs a sleazy blog and has "crept around in the background" as a paid basher of LXX.  I say sleazy because even his own website manipulates all the links of the LXX press releases to support his bashing interests.  
Chris knows damn well the company's patent has been ISSUED.  Anyone with a half a brain can read the latest press release on Stockhouse.  Yet on Thursday Chris' followers blindly sold stock based on his distortion of a weak press release (which is not even on Stockhouse) that manipulated the truth.  Sure, the press release about cutting tea prices was lame. But to use it to manipulate people away from the truth of the pantent ISSUANCE, and the company's business model is simply sleazy.  It's time to "call him out on it".
I look forward to the day LXX signs a royalty deal with one of his favorite MJ companies.
Chris - just in case you actually don't know what "patent allowed" actually means, you can find the USPTO link below.  And instead of bashing, why didn't you educate your follows about LXX's patent allowance in July, and help them release that it's a game changer for the company?  Oh, right, I forgot - that's when some company got quite nervous about the potential magnitude of this patent and started paying you to crush the company... got it...
https://www.uspto.gov/web/offices/pac/mpep/s203.html

Bullboard Posts